DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.

A number of other analysts have also commented on DBVT. JMP Securities reissued a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th. HC Wainwright boosted their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Stock Performance

DBVT opened at $4.26 on Tuesday. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.09. The company has a market capitalization of $87.63 million, a P/E ratio of -0.95 and a beta of 0.67. The stock has a fifty day moving average of $3.97 and a 200-day moving average of $3.84.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.